Microbial Amadori Deglycation (Amadoriase / FAOX / FAOD)

Amadoriase — also called fructosyl-amino-acid oxidase (FAOX), fructosyl amino oxidase (FAOD), or fructosyl peptide oxidase (FPOX) — is a class of FAD-dependent flavoenzymes found in soil fungi and bacteria that catalyze oxidative cleavage of fructosyl-amino-acid bonds (Amadori products). The reaction releases glucosone + the free amino acid + H₂O₂. These enzymes have been used commercially in HbA1c diagnostics for decades and represent, alongside mammalian fn3k, the only known enzymatic routes for deglycation — defined here as reversal of early-Maillard Amadori products.

Unlike fn3k (phosphorylative, intracellular, vertebrate), FAOX/FAOD enzymes are oxidative, extracellular-compatible (secreted or surface-associated in soil organisms), and have substrate scope that may extend beyond simple fructosyl-lysine to include some mature (non-crosslink) AGE adducts, per Delanghe et al. 2024 (see below). They constitute Tier 2 of the natural AGE-defense framework alongside FN3K — see advanced-glycation-end-products § “Three-tier natural defense framework.”

Discovery and microbial source organisms

Amadoriase activity was first described in soil-dwelling microorganisms that subsist on glycated proteins as nitrogen and carbon sources. Characterized source organisms include:

Aspergillus fumigatus, Aspergillus nidulans — early cloning and characterization; the A. nidulans faoA gene (441 amino acids; inducible by fructosyl-propylamine and fructosyl-lysine) was characterized by Jeong et al. 2002 ¹.
Eupenicillium terrenum — fructosyl peptide oxidase with high specificity toward α-glycated molecules including fructosyl-Val-His (the HbA1c diagnostic substrate) ².
Penicillium janthinellum, Coniochaeta — additional sources with varying specificity profiles ³.
Various Corynebacterium and Bacillus strains harbor amadoriase-like activities.

Two functional subclasses were recognized early ³:

α-glycated preferring (Class A) — high specificity toward α-glycated molecules; act on N-terminal fructosyl-amino groups (e.g., fructosyl-Val-His, the HbA1c diagnostic substrate).
ε-glycated preferring (Class B) — preferentially oxidize ε-glycated molecules; act on fructosyl-lysine side-chain adducts.

Note: the classification from Hirokawa 2003 is α- vs ε-glycation specificity, not “free amino acid-specific vs peptide-permissive” as previously stated. Both classes can be relevant for diagnostic applications; Class A enzymes are the ones used in HbA1c measurement.

Catalytic mechanism

Amadoriase is a FAD-dependent oxidase (not a kinase like FN3K). The reaction is fundamentally oxidative:

Fructosyl-R-NH₂ + O₂ + H₂O → glucosone + R-NH₂ + H₂O₂

Where R-NH₂ is the free amino acid (e.g., lysine, valine) or the N-terminus of a glycated peptide. The FAD cofactor accepts electrons from the substrate, then transfers them to O₂, producing H₂O₂.

Mechanistic difference from FN3K: FN3K is phosphorylative (ATP + fructosamine → ADP + fructosamine-3-P → 3-DG + free amine + Pi). FAOX/FAOD is oxidative (O₂ → glucosone + H₂O₂). Neither releases the same by-products:

FN3K by-product: 3-deoxyglucosone (another reactive α-dicarbonyl; requires further detoxification by glo1 pathway metabolons or AKR enzymes).
FAOX/FAOD by-product: glucosone (less reactive than 3-DG) + H₂O₂ (cytotoxic; the primary concern for therapeutic deployment).

Classical substrate scope — diagnostic applications

For the HbA1c assay, the key substrate is fructosyl-valine (N-terminal Val of the β-chain, after incubation of blood with a protease to release the dipeptide fructosyl-Val-His). The FAOD enzyme in point-of-care HbA1c analyzers (Tosoh, Roche, and others) cleaves this substrate, and the resulting H₂O₂ is detected colorimetrically via peroxidase + chromogen. This is a mature commercial application with decades of clinical use ².

Substrate scope — classical view:

Fructosyl-lysine ✓ (ε-glycated, Class B enzymes)
Fructosyl-valine ✓ (α-N-terminal glycated — the HbA1c diagnostic substrate; Class A enzymes, particularly Eupenicillium terrenum FPOX)
Fructosyl-phenylalanine ✓ (varies by enzyme subtype)
Protein-bound fructosyl-lysine: accessible after prior protease treatment for most enzymes; Class A enzymes act on α-N-terminal substrates without protease pre-treatment
Mature AGEs (CML, CEL, imidazolone, glucosepane, pentosidine): historically considered NOT substrates — but see Delanghe 2024 below.

Verhoekx 2024 / Delanghe 2024 — expanded substrate scope in AMD

Delanghe et al. 2024 (Int J Mol Sci) is the highest-impact recent paper in this area and substantially expands the known substrate scope of FAOD ⁴. The key findings from the abstract (full PDF verification pending):

Model systems: (a) glycolaldehyde-glycated porcine retinas (ex vivo); (b) human AMD retinal sections (ex vivo).

Significant endpoints (as reported in abstract):

AGE autofluorescence reduced by FAOD treatment in glycolaldehyde-treated porcine retinas (p = 0.001).
Drusen surface area reduced to 45 ± 21% of control in human AMD retinal sections following FAOD treatment.

Substrate scope finding: Mass spectrometry revealed FAOD cleaves a broader substrate panel than previously established, including fructosyl-lysine, CML (carboxymethyllysine), CEL (carboxyethyllysine), and imidazolone — adducts beyond simple Amadori products. This is the first report of a natural enzyme acting on CML and CEL in tissue.

Agmatine release: The authors observed release of agmatine (4-aminobutyl-guanidine) during FAOD treatment, suggesting guanidino-bond cleavage in addition to N-glycoside hydrolysis — a mechanistically unexpected finding.

Absence of glucosepane/pentosidine data: The paper did not report FAOD activity against glucosepane or pentosidine. CML and CEL are monovalent lysine/arginine modifications — NOT bifunctional crosslinks. The mature crosslinks (glucosepane, pentosidine) remain without any known natural enzyme capable of cleavage as of 2026-05-20.

Interpretation for the field: The Delanghe 2024 result is significant because it establishes that a natural enzyme can act on at least some mature (non-Amadori) AGE adducts. However, it does not close the glucosepane/pentosidine gap — the adducts it acts on are non-crosslinking single-site modifications. The clinical translation of FAOD for AMD is speculative but represents the first ex-vivo human-tissue evidence for enzymatic AGE reduction in a disease-relevant context.

needs-replication — Delanghe 2024 (PMID:38732004) key quantitative claims (p=0.001 autofluorescence reduction; 45±21% drusen surface area reduction; substrate scope fructosyl-Lys/CML/CEL/imidazolone; agmatine release; glucosepane/pentosidine not tested) confirmed via two independent PubMed abstract queries. Sample sizes (n values) for individual experiments not reported in abstract. Full PDF not read; n values and additional methodological details remain to be confirmed. Single-study; no independent replication of the expanded substrate scope.

Dimension	Status
Pathway conserved in humans?	Not applicable (microbial enzyme; human relevance is therapeutic, not endogenous)
Phenotype conserved in humans?	Not applicable
Replicated in humans?	No — ex-vivo tissue sections only (Delanghe 2024); no in-vivo human data

Commercial use and clinical-diagnostics engineering

FAOD has been commercially deployed in HbA1c assays for >20 years. Engineered variants with altered substrate specificity — particularly expanded peptide-substrate acceptance for fructosyl-Val-His on intact hemoglobin after restricted protease pre-treatment — have been developed by multiple groups ³ ². This engineering precedent is relevant to therapeutic deployment: FAOD is a tractable enzyme for directed evolution to broaden or narrow substrate scope, modify oxidative by-product handling, or reduce immunogenicity.

Combination therapy with FN3K — De Decker 2023

De Decker et al. 2023 (Int J Mol Sci; PMID 37240327) demonstrated that combining FAOD with the mammalian deglycating enzyme FN3K achieved ~43% autofluorescence reduction in glycolaldehyde-damaged human skin specimens — outperforming FAOD monotherapy (33%), FN3K monotherapy (31%), and the positive control aminoguanidine (28%) ⁵. This is the first published combination-therapy precedent for FAOD and FN3K acting synergistically in human tissue.

The additive effect is mechanistically consistent: FAOD operates preferentially on extracellular and surface-accessible glycated amino groups (including CML and CEL per Delanghe 2024), while FN3K acts on intracellular fructosyl-lysine substrates in the tissue. Because the two enzymes attack non-overlapping substrate pools via different mechanisms (oxidation vs. phosphorylation), combined application covers a broader fraction of total skin glycation burden without competition.

Caveats: The study used an acute glycolaldehyde dimer-induction model (25 mM, 3 h) in young skin (not chronic, physiologically glycated aged skin); combined FAOD + FN3K generates additive by-products (H₂O₂ + 3-deoxyglucosone); cytotoxicity of co-delivered by-products was not assessed. See de-decker-2023-fn3k-faod-skin-combination for full design and findings.

Therapeutic limitations

H₂O₂ release: The catalytic mechanism releases H₂O₂ as a stoichiometric by-product. At therapeutic concentrations, H₂O₂ is cytotoxic and pro-inflammatory. Mitigation strategies include co-delivery of catalase (H₂O₂ → H₂O + ½O₂); engineered FAOD–catalase fusion proteins are a proposed solution. This co-delivery requirement adds complexity and potential immunogenicity.
Immunogenicity: Fungal/bacterial proteins are antigenic in mammals. Repeated systemic dosing of a fungal enzyme would likely elicit antibody responses that neutralize activity and/or cause hypersensitivity reactions. Humanization or PEGylation would be required.
Tissue penetration: Protein therapeutics have limited penetration into compacted ECM-rich tissues (arterial adventitia, dermis). Intravitreal injection (for AMD) partially bypasses this — the vitreous and subretinal space are more accessible. Systemic collagen deglycation would require delivery to dense ECM environments.
Substrate scope still excludes crosslinks: Even after Delanghe 2024, the major structural problem in aging ECM — glucosepane-crosslinked collagen fibrils — appears to be outside the substrate range of all known FAOX/FAOD variants.
Cofactor stability: FAD cofactor is susceptible to inactivation by oxidative conditions, which are elevated in AGE-rich tissues. Engineered FAOD variants with improved cofactor stability would be required.

Relation to Revel Pharmaceuticals / Spiegel-lab functional-metagenomics program

Revel Pharmaceuticals’ founding premise was that soil-metagenome-encoded enzymes capable of cleaving mature glucosepane crosslinks should exist in organisms that catabolize aged proteins as nutrient sources. FAOX/FAOD is the known class in this space — characterized as capable of Amadori-product deglycation and now (per Delanghe 2024) some non-crosslink mature AGE adducts. However, FAOX/FAOD does not close the glucosepane gap.

If FAOD’s expanded substrate scope (Delanghe 2024) is confirmed, it strengthens the broader hypothesis that fungal/bacterial flavoenzymes can have unexpectedly broad AGE-substrate scope — supporting the plausibility of Revel’s metagenomics approach. But it does not constitute the glucosepane-cleaving enzyme the program sought. See age-crosslink-breakers § “Natural enzymatic AGE clearance — three-tier defense framework.”

Limitations and gaps

Glucosepane and pentosidine crosslinks remain without any known enzymatic cleavage route. Tier 3 of the natural defense hierarchy is empty.
Delanghe 2024 expanded substrate scope needs independent replication. CML and CEL cleavage by FAOD is a single-laboratory finding; the mechanism of guanidino-bond cleavage (agmatine release) is unexpected and requires mechanistic follow-up.
Therapeutic deployment faces H₂O₂ toxicity, immunogenicity, and ECM penetration barriers — each representing an engineering challenge without validated solutions as of 2026.
No in-vivo animal efficacy data for any therapeutic application of FAOD have been published. AMD is a promising target (intraocular access; drusen as accessible deposits), but the Delanghe 2024 evidence is ex-vivo sections only.
Soil-ecology context: Soil microbes likely catabolize AGE-containing proteins primarily through broad-specificity proteases fragmenting the protein backbone near crosslinks, not through crosslink-specific enzyme chemistry. The functional diversity of AGE-targeting microbial enzymes may be greater than currently characterized. no-mechanism for full enzyme diversity.

Footnotes

doi:10.1007/s00203-002-0463-x · Jeong HY, Song MH, Back JH, Han DM, Wu X, Monnier V, Jahng KY, Chae KS · Arch Microbiol 2002;178(5):344–50 · PMID:12375102 · in-vitro · model: Aspergillus nidulans faoA gene characterization · gene encodes 441 aa enzyme with 5 introns; single copy gene; inducible by fructosyl amines; veA gene required for full induction; enzyme dispensable for normal A. nidulans development/growth · abstract-level via PubMed no-fulltext-access ↩
doi:10.1016/j.femsle.2004.04.027 · Hirokawa K, Nakamura K, Kajiyama N · FEMS Microbiol Lett 2004;235(1):157–62 · PMID:15158276 · in-vitro · Eupenicillium terrenum FPOX; high specificity toward α-glycated fructosyl-Val-His; clinical HbA1c measurement application · abstract-level via PubMed no-fulltext-access ↩ ↩² ↩³
doi:10.1016/j.bbrc.2003.09.169 · Hirokawa K, Gomi K, Kajiyama N · Biochem Biophys Res Commun 2003;311(1):104–11 · PMID:14575701 · in-vitro · molecular cloning and expression of novel fructosyl peptide oxidases; two functional subclasses identified (free amino acid-specific vs peptide-permissive); HbA1c measurement application · abstract-level via PubMed no-fulltext-access ↩ ↩² ↩³
doi:10.3390/ijms25094779 · Delanghe JR, Diana Di Mavungu J, Beerens K, Himpe JJ, Bostan N, Speeckaert MM, Vrielinck H, Vral A, Van Den Broeke C, Huizing M, Van Aken E · Int J Mol Sci 2024;25(9):4779 · PMID:38732004 · ex-vivo · model: glycolaldehyde-glycated porcine retinas + human AMD retinal sections · AGE autofluorescence reduced (p=0.001 in porcine model); drusen surface area reduced to 45 ± 21% of control in human AMD sections; substrate scope included fructosyl-lysine, CML, CEL, imidazolone (by MS); agmatine released (guanidino-bond cleavage); glucosepane and pentosidine cleavage NOT reported · archive: OA gold (MDPI); download pending (PMID:38732004) · abstract-only verification; full PDF required for quantitative claim confirmation no-fulltext-access ↩
de-decker-2023-fn3k-faod-skin-combination · n=19 skin specimens (healthy breast skin, mean age 26 ± 9 years) · in-vitro (ex-vivo glycolaldehyde dimer model; 25 mM, 3 h, 37°C) · model: human breast skin specimens · FAOD alone −33% AF (p<0.0001); FN3K+FAOD −43% AF (p<0.0001); FN3K alone −31% (p<0.0001); aminoguanidine −28% (p<0.001) · AF: excitation 370 nm / emission 390–700 nm · full PDF verified 2026-05-20 (doi:10.3390/ijms24108981) ↩

🧬 Aging Wiki

Explorer

microbial-amadori-deglycation